Comparison of Korean COPD guideline and GOLD initiative report in term of acute exacerbation: A validation study for Korean COPD guideline

Journal of Korean Medical Science

Volumn 29, Issue 8, 2014, Pages 1108-1112

  Hwang, Yong Il ^a   Park, Yong Bum ^a   Oh, Yeon Mok ^b   Lee, Ji Hyun ^c   Kim, Tae Hyung ^d   Yoo, Kwang Ha ^e   Yoon, Hyoung Kyu ^f   Rhee, Chin Kook ^g   Kim, Deog Kyeom ^h   Shin, Kyeong Cheol ⁱ   Lee, Sang Yeub ^j   Jung, Ki Suck ^a  

^a Hallym University Medical Center   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c CHA University   (South Korea)

^d Hanyang University Guri Hospital   (South Korea)

^e Konkuk University School of Medicine   (South Korea)

^f The Catholic University of Korea College of Medicine   (South Korea)

^g The Catholic University of Korea   (South Korea)

^h Seoul National University Boramae Hospital   (South Korea)

ⁱ Yeungnam University College of Medicine   (South Korea)

^j College of Medicine   (South Korea)

more..

Author keywords

Assessment; COPD; Exacerbation; FEV1; Guidelines

Indexed keywords

ACUTE DISEASE; AGED; CLASSIFICATION; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; EVALUATION STUDY; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PRACTICE GUIDELINE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SOUTH KOREA; SPIROMETRY; STANDARDS; VALIDATION STUDY;

ACUTE DISEASE; AGED; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY MEDICINE; REPRODUCIBILITY OF RESULTS; REPUBLIC OF KOREA; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SPIROMETRY;

EID: 84937553517     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2014.29.8.1108     Document Type: Article

References (13)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Workshop Report, National Institutes of Health. National Heart, Lung, and Blood Institute. Publication Number 2701. 2001.
2. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-38.
3. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and Prevent of chronic obstructive pulmonary disease, updated 2014. Available at http://www.goldcopd.org [accessed on 5 February 2014].
4. Han MK, Muellerova H, Curran-Everett D, Dransfield MT, Washko GR, Regan EA, Bowler RP, Beaty TH, Hokanson JE, Lynch DA, et al. GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med 2013; 1: 43-50.
5. Lange P, Marott JL, Vestbo J, Olsen KR, Ingebrigtsen TS, Dahl M, Nordestgaard BG. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med 2012; 186: 975-81.
6. Soriano JB, Alfageme I, Almagro P, Casanova C, Esteban C, Soler-Cataluña JJ, de Torres JP, Martinez-Camblor P, Miravitlles M, Celli BR, et al. Distribution and prognostic validity of the new Global Initiative for Chronic Obstructive Lung Disease grading classification. Chest 2013; 143: 694-702.
7. Johannessen A, Nilsen RM, Storebø M, Gulsvik A, Eagan T, Bakke P. Comparison of 2011 and 2007 Global Initiative for Chronic Obstructive Lung Disease guidelines for predicting mortality and hospitalization. Am J Respir Crit Care Med 2013; 188: 51-9.
8. Korean Academy of Tuberculosis and Respiratory Diseases. COPD guideline revised 2012. Available at http://www.lungkorea.org/thesis/guide.php [accessed on 5 February 2014].
9. Agusti A, Hurd S, Jones P, Fabbri LM, Martinez F, Vogelmeier C, Vestbo J, Rodriguez-Roisin R. FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. Eur Respir J 2013; 42: 1391-401.
10. Jung KS, Park HY, Park SY, Kim SK, Kim YK, Shim JJ, Moon HS, Lee KH, Yoo JH, Lee SD. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respir Med 2012; 106: 382-9.
11. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J; TORCH Investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-89.
12. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C; TRial of Inhaled STeroids ANd long-acting beta2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-56.
13. Yoo KH, Kim YS, Sheen SS, Park JH, Hwang YI, Kim SH, Yoon HI, Lim SC, Park JY, Park SJ, et al. Prevalence of chronic obstructive pulmonary disease in Korea: the fourth Korean National Health and Nutrition Examination Survey, 2008. Respirology 2011; 16: 659-65.